|
MechanismHIV envelope protein gp120 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Interventional / Prospective Phase III Accelerated Study to Determine The Efficacy & Safety of RECEPTOL Oral Spray Used As A Stand-Alone Mono Therapy In HIV / AIDS Patients with multiple symptoms
100 Clinical Results associated with Biomix Network Ltd.
0 Patents (Medical) associated with Biomix Network Ltd.
100 Deals associated with Biomix Network Ltd.
100 Translational Medicine associated with Biomix Network Ltd.